Filing Flows › Biomerica (BMRA) › Q1 FY27 › vs Q1 FY26
Biomerica (BMRA) Q1 FY27 vs Q1 FY26 (year over year)
Biomerica's revenue fell $115K (-8%) from $1.4M in Q1 FY26 to $1.3M in Q1 FY27. The biggest changes: Clinical Lab −$249K (-24%); Over-the-counter +$130K (+81%); Contract Manufacturing +$5K (+3%).
Biomerica, Q1 FY27: revenue $1.3M (-8% year over year), operating margin -97.0%, net loss $1.2M, operating cash flow −$802K. The chart draws each line against Q1 FY26, the increases inside each band.
Every line
| Line | Q1 FY27 | Q1 FY26 | Change | % |
|---|---|---|---|---|
| Clinical Lab | $775K | $1.0M | −$249K | -24% |
| Over-the-counter | $291K | $161K | $130K | +81% |
| Contract Manufacturing | $197K | $192K | $5K | +3% |
| Physician's Office | $2K | $3K | −$1K | -33% |
| Revenue | $1.3M | $1.4M | −$115K | -8% |
| Net loss | $1.2M | −$2K | $1.2M | — |
| Costs & expenses | $2.5M | $2.5M | −$5K | -0.2% |
| Operating costs | $2.5M | $2.5M | −$6K | -0.2% |
| Income tax | $6K | $3K | $3K | +100% |
| Cost of revenue | $1.2M | $956K | $206K | +22% |
| Research & development | $206K | $212K | −$6K | -3% |
| SG&A | $1.1M | $1.3M | −$206K | -15% |
| Operating cash sources | $1.2M | −$2K | $1.2M | — |
| Depreciation & amortization | $15K | $20K | −$5K | -25% |
| Share-based compensation | $134K | $133K | $1K | +0.8% |
| Working capital & other | $281K | −$423K | $704K | — |
| Cash used in operations | $802K | $268K | $534K | +199% |
| Net loss absorbed | $1.2M | −$2K | $1.2M | — |
Questions
How much did Biomerica's revenue grow year over year in Q1 FY27?
Biomerica's revenue fell $115K (-8%) from $1.4M in Q1 FY26 to $1.3M in Q1 FY27.
What drove Biomerica's revenue change in Q1 FY27?
Clinical Lab −$249K (-24%); Over-the-counter +$130K (+81%); Contract Manufacturing +$5K (+3%).